JAGX Jaguar Health Inc.

0  -0%
Previous Close 0.18
Open 0.19
Price To Book 3.58
Market Cap 17849214
Shares 99,716,279
Volume 2,256,176
Short Ratio
Av. Daily Volume 9,734,853

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data due 1H 2019.
Mytesi (crofelemer)
Cancer related diarrhea (CRD)
Protocol development for discussions with FDA.
Mytesi (crofelemer)
Inflammatory bowel disease (IBD)

Latest News

  1. Jaguar Health Donates Supply of Mytesi to Humanitarian Aid Organization Direct Relief
  2. Jaguar Health, Inc. Reports 2018 Fourth Quarter and Year End Financial Results
  3. Jaguar Health Subsidiary Napo Pharmaceuticals Issues Further Regulatory Update Regarding Potential Follow-on Indication for Mytesi
  4. Jaguar Health, Pipeline Review and Progress
  5. Jaguar Health Issues Regulatory Update Regarding Potential Follow-on Indication for Mytesi
  6. Four Biotech Stocks Setting The Standard On Wednesday
  7. Jaguar Completes Filing of CMC Technical Section with FDA for Use of Canalevia for Treatment of Chemotherapy-Induced Diarrhea in Dogs
  8. Four Healthcare Stocks Heating Up On Monday
  9. Jaguar Health, Inc. Reports Voting Results from February 28, 2019 Special Meeting of Stockholders
  10. Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Thursday, February 28, 2019
  11. What Kind Of Shareholders Own Jaguar Health, Inc. (NASDAQ:JAGX)?
  12. With the Addition of Mytesi to the Formulary for Florida's AIDS Drug Assistance Program (ADAP), Approximately 86% of ADAP-Eligible US Lives Now Have Access to Jaguar Health's FDA-Approved Drug Product
  13. Jaguar Health to Present at Noble Capital Markets Annual Investor Conference January 28 in Fort Lauderdale
  14. Jaguar Health Receives First Order for First-Generation of Equilevia, the Company's Non-Prescription, Personalized, Premium Product for Total Gut Health in High-Performance Equine Athletes
  15. Jaguar Health Provides Fourth Quarter 2018 Commercial Sales Updates
  16. Jaguar Health to Present at Biotech Showcase 2019 in San Francisco
  17. Jaguar Health to Host Investor Call January 7th at 8 a.m. Eastern to Review 4Q'18 Performance
  18. Jaguar Health, Inc. Engages T.R. Winston & Company to Advise on Collaboration, Licensing and Development Activities Related to Mytesi and Crofelemer
  19. Jaguar Health, Inc. Reports Third-Quarter 2018 Results
  20. Reminder: Jaguar Health, Inc. Will Release 3Q'18 Financial Results After Market on November 14th